ArticleJournal of orthopaedic surgery and research2026
miR-376c-3p mediates icariin's anti-osteoclastogenic effect by targeting Mmp3.
Article in Journal of orthopaedic surgery and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMicroRNAs (miRNAs) are crucial regulators of osteoclast differentiation. Icariin (ICA), the primary active constituent of the traditional Chinese herb Epimedium, has been shown to inhibit osteoclastogenesis. However, whether ICA suppresses osteoclast differentiation via miRNA regulation remains to be elucidated.
methodsWe employed bioinformatic analysis coupled with in vivo validation to screen for and identify potential targets that mediate the effects of ICA on osteoclast formation. Subsequently, we carried out in vitro experiments involving the overexpression and knockdown of miR-376c-3p in bone marrow-derived macrophages (BMMs). Additionally, luciferase reporter assays and western blot analysis were utilized to ascertain the direct targets of miR-376c-3p.
resultsIt was confirmed that miR-376c-3p plays a regulatory role in osteoclast differentiation within bone marrow-derived macrophages (BMMs). Notably, the knockdown of miR-376c-3p led to a partial reversal of the inhibitory effect that ICA exerts on osteoclastogenesis. Furthermore, matrix metalloproteinase-3 (Mmp3) was validated as a direct target of miR-376c-3p, providing evidence to suggest that ICA likely mediates its effects through the miR-376c-3p/Mmp3 signaling axis.
conclusionOur findings demonstrate that ICA exerts its anti-osteoporotic effect by downregulating the miR-376c-3p-mediated Mmp3 expression. This study provides insights that potentially facilitate ICA's clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.